ResMed (RMD) recently combined a CFO transition with quarterly results that showed higher sales, net income and earnings per share year over year, a mix that tends to sharpen investor focus on the stock.
See our latest analysis for ResMed.
Even with higher quarterly sales and earnings, ResMed’s recent share price has been under pressure, with a 30 day share price return of an 8.48% decline and a 90 day share price return of a 23.83% decline. The 1 year total shareholder return of a 14.31% decline suggests momentum has been fading over a longer stretch as the market digests the CFO transition, buybacks and dividend affirmation.
If this kind of earnings and leadership story has you thinking about where growth and risk might show up next in healthcare, it could be worth scanning 35 healthcare AI stocks
With earnings, buybacks and a new CFO all in focus, the recent share price slide and management’s own view of intrinsic value raise a simple question for you: Is ResMed now undervalued or is future growth already priced in?
Most Popular Narrative: 28.2% Undervalued
ResMed's most followed narrative points to a fair value meaningfully above the last close at $206.89. This puts the recent share price slide in a different light.
Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time.
Curious what kind of revenue mix, margin profile and earnings roadmap sit behind that valuation gap, and how long the narrative expects them to hold up.
Result: Fair Value of $288.21 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on reimbursement and competitive trends. Tighter CMS bidding or faster adoption of alternative sleep apnea treatments are both capable of upending those assumptions.
Find out about the key risks to this ResMed narrative.
Next Steps
If the combination of strong earnings and share price pressure seems conflicting, do not remain on the sidelines. Instead, review the 4 key rewards.
Looking for more investment ideas?
If ResMed has sharpened your thinking about risk and reward, do not stop here. Broaden your watchlist with a few targeted stock ideas sourced from data driven filters.
- Spot potential value opportunities early by checking stocks highlighted in the 51 high quality undervalued stocks.
- Prioritise balance sheet strength by reviewing companies surfaced by the solid balance sheet and fundamentals stocks screener (44 results).
- Hunt for lesser known opportunities by scanning the screener containing 23 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com